Preconception and peptides — what to discontinue before trying to conceive

That gap is surprisingly common. Reproductive medicine and the peptide space don't have a clean interface. Your OB-GYN may have limited familiarity with compounded peptides. Your peptide prescriber may not be thinking about preconception timing. The responsibility for connecting those dots often falls on you.

Here is the framework for thinking about it.

The foundational principle is conservative and unambiguous: essentially all wellness peptides are contraindicated during pregnancy. Not because every one of them has demonstrated harm in human studies, but because essentially none of them have been tested for fetal safety, because the standards for pregnancy safety research are appropriately high, and because the risk-benefit calculation for elective wellness protocols shifts completely when a developing embryo is involved. This isn't a close call. The question isn't which peptides are safe to continue during pregnancy. The question is how far in advance of trying to conceive you should stop, and what the washout logic looks like for each class.

GLP-1 receptor agonists are the category with the most evolving guidance, in part because they're the most widely prescribed. For short-acting GLP-1 agonists, current guidance from the major reproductive societies recommends discontinuing before attempting conception — the specific washout window has varied across different guidelines but has been in the range of two months for shorter-acting agents. For long-acting forms like semaglutide, the recommendation has been longer — around two months minimum, with some guidance suggesting longer to allow full clearance given the extended half-life. This is actively evolving territory; the specific numbers may shift as more data accumulates, and your prescribing provider and reproductive endocrinologist need to be aligned on the current recommendation for whatever agent you're on. The underlying rationale is fetal safety data gaps, not confirmed teratogenicity — but in reproductive medicine, unconfirmed safety is treated as insufficient safety.

GH-axis peptides — sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677, and related compounds — should be discontinued for pregnancy planning. Growth hormone and IGF-1 signaling play important roles in fetal development, but those roles are orchestrated by the fetus's own emerging endocrine system, not by exogenous maternal stimulation of GH secretagogue pathways. The concern isn't that these peptides are proven harmful in pregnancy; it's that they haven't been studied in that context, and the growth-factor signaling they influence is not a system you want to be perturbing with exogenous compounds during fetal development. Discontinue before attempting conception with guidance from your prescribing provider on timing based on the specific compound and its half-life.

BPC-157 and TB-500 require particular attention in the preconception window. Both have been researched for their roles in angiogenesis — the formation of new blood vessels — and tissue repair. That angiogenic activity is part of what makes them interesting in recovery contexts. It is also a mechanism with direct implications for fetal development, where angiogenesis is tightly regulated and where exogenous stimulation of that process is not something that has been studied or should be assumed safe. The absence of pregnancy safety data, combined with the biological plausibility of interference with placentation and fetal vascular development, makes these a clear discontinuation before trying to conceive.

Melanocortin peptides — Melanotan II and PT-141 — carry specific teratogenicity concerns and should be discontinued well before attempting conception. Melanotan II in particular has been associated with concerning reproductive effects in animal models, and the lack of human reproductive safety data is not a neutral finding. These are not compounds to be tapering down as you enter the conception window. They stop before the window opens.

All research peptides — any compound that lacks FDA approval, established clinical use, and human reproductive safety data — fall into a straightforward category: not appropriate during the preconception window, not appropriate during pregnancy, not appropriate while breastfeeding. The reasoning is the same for all of them. Absence of evidence of harm is not evidence of absence of harm. The developing embryo cannot consent to exposure to experimental compounds, and the ethical and medical standard is accordingly precautionary.

There is one category that operates under different logic: peptides used in fertility protocols under reproductive endocrinology supervision. HCG — human chorionic gonadotropin — is specifically used in fertility medicine to trigger ovulation and support early luteal phase function. Kisspeptin analogs are being studied in IVF protocols for their role in gonadotropin stimulation. These are not wellness peptides; they are pharmacological tools in medical fertility treatment, and their use is supervised by reproductive endocrinologists who are actively managing your cycle. They belong in a different category entirely — the category of medically directed fertility treatment — and their use is planned and monitored rather than self-directed.

The preconception window is also a productive moment to address the underlying goals of your peptide protocol through other means. If peptides have been part of a metabolic optimization strategy — managing body composition, improving insulin sensitivity, supporting glucose regulation — the preconception period is the time to consolidate those gains with lifestyle approaches that will serve you through pregnancy and beyond. Weight optimization before conception is genuinely associated with better reproductive outcomes and a healthier pregnancy arc. Achieving that through approaches that don't involve compounds with unknown fetal safety is the appropriate goal. This isn't about abandoning the progress you've made; it's about translating it into a form that doesn't carry the uncertainty of exogenous peptide use during a developmental window.

The mental health dimension of this transition deserves honest acknowledgment. Stopping interventions that have been supporting mood, energy, sleep, and body composition — while simultaneously managing the psychological weight of trying to conceive, which carries its own anxiety regardless of history — is a real stress. Planning the discontinuation timeline gives you room to address that. If some of the mood and energy support from peptide protocols was compensating for underlying things — stress, sleep insufficiency, nutrition gaps — the preconception window is the time to address those foundations directly, not to wonder why stopping peptides is harder than expected.

The timing of washout depends on the specific compound, its half-life, its mechanism, and your individual circumstances. There is no single universal answer. What there is a universal answer to is the need for coordination: your reproductive endocrinologist or OB-GYN and your prescribing provider need to be in communication about what you're taking, what the washout plan is, and what the timeline looks like. This is not a conversation to have with one but not the other, or to manage privately by stopping things on a schedule you assembled from internet research.

The preconception window is a brief and important one. Using it to systematically reduce exogenous compound use, optimize the underlying foundations of health, and align your care team around a shared plan is the most protective and productive approach available. The optimization mindset that served you in the years before doesn't disappear — it redirects toward a different goal, with a different risk profile, and a different definition of what careful management looks like.